How to Reduce Cost, Risk, and Rework in Audit Risks and Legal Exposure Management

Context

In the highly regulated environments of the US, UK, and EU, pharmaceutical and biotech companies must navigate a complex web of laws and regulations governing controlled substances. These regulations primarily aim to prevent misuse and ensure public safety. However, they pose significant audit risks and potential legal exposure if not managed correctly. Regulatory Affairs (RA) professionals play a critical role in ensuring compliance with these regulations while minimizing risks associated with audits and legal scrutiny.

Legal/Regulatory Basis

The management of audit risks and legal exposure related to controlled substances is grounded in various regulations and guidelines issued by major authorities. Key references include:

• 21 CFR Part 1300-1399 – The Code of Federal Regulations Title 21 governs the legal standards for controlled substances in the United States, set by the FDA.
• EU Regulation No. 2017/746 – This regulation outlines the framework for in vitro diagnostic medical devices but has implications for compliance with controlled substances within the EU market.
• MHRA Guidelines – The UK Medicines and Healthcare products Regulatory Agency provides specific guidance that overlaps with both EU and US legislation, with particular focus on narcotic drugs and their monitoring.

Compliance with these regulations is crucial not only to avoid legal repercussions but also to ensure the integrity of product supply and corporate reputation.

Documentation

Effective documentation practices are fundamental to controlling audit risks and legal exposure management. Regulatory Affairs teams must ensure that all aspects of controlled substances compliance are well-documented. This includes:

• Licenses and Permits: Validate that all necessary licenses for handling controlled substances are current and accessible.
• Standard Operating Procedures (SOPs): Maintain detailed SOPs that adhere to regulatory requirements and ensure proper handling, storage, and disposal of controlled substances.
• Training Records: Document training performed with staff on compliance requirements related to controlled substances, which is essential for demonstrating adherence during audits.
• Inventory Controls: Regularly perform audits on controlled substance inventories, documenting discrepancies and actions taken to rectify them.

Documentation should be readily accessible to facilitate efficient auditing processes, which helps to mitigate risks of non-compliance and potential penalties.

Review/Approval Flow

The review and approval flow for audit risks and legal exposure management involves several critical steps:

1. Identifying Controlled Substances: Assess which substances are under the definition of controlled substances as per local regulations.
2. Risk Assessment: Conduct a thorough risk assessment that includes identifying potential points of legal exposure, as well as evaluating security controls in place to mitigate these risks.
3. Documentation Preparation: Ensure all required documentation and records are in order for review, including compliance data, training records, and audit results.
4. Internal Review: If applicable, conduct an internal review by Quality Assurance (QA) to ensure that all documentation meets regulatory standards and that audit risks are minimized.
5. Submission to Regulatory Authority: Prepare and submit all documentation to the relevant authorities, ensuring it meets specific agency expectations.
6. Follow-Up and Response: Be prepared to respond to agency queries or requests for additional information swiftly, maintaining a collaborative relationship with regulators.

Common Deficiencies

Understanding common deficiencies in audit risks and legal exposure management can significantly enhance a company’s inspection readiness. Some typical issues include:

• Lack of Up-to-Date Documentation: Failing to keep documentation current can lead to significant gaps during audits and increase legal exposure.
• Poor Inventory Management: Inconsistent inventory controls raise red flags during inspections, potentially leading to regulatory actions and compliance failures.
• Inadequate Training Programs: Without proper training programs for staff handling controlled substances, organizations can face scrutiny over compliance and safety protocols.
• Failure to Conduct Regular Audits: Neglecting routine internal audits can expose companies to risks that are entrenched rather than easily identifiable.

Interplay with Other Departments

Regulatory Affairs teams do not operate in isolation; effective audit risks and legal exposure management require collaboration across various departments:

• Clinical: Collaboration with Clinical teams ensures that data related to controlled substances used in clinical trials is documented properly and adheres to regulatory standards.
• Pharmacovigilance (PV): Regulatory Affairs must liaise with PV departments to ensure that safety reporting for controlled substances complies with local regulations.
• Quality Assurance (QA): The QA team plays an essential role in auditing compliance activities, which contributes to the overall risk management framework.
• Commercial: Ensuring commercial teams are aware of regulatory restrictions on marketing and distribution of controlled substances is key in preventing legal pitfalls.

Regulatory Risk Management Strategies

To effectively manage regulatory risks associated with controlled substances, companies should consider the following strategies:

• Conduct Regular Compliance Training: Regular and comprehensive training for employees handling controlled substances will minimize risks related to non-compliance.
• Implement Robust Security Controls: Establish physical and procedural controls to secure controlled substances, preventing unauthorized access and misuse.
• Establish Clear Reporting Mechanisms: Develop internal channels for reporting compliance issues or discrepancies to ensure swift resolution.
• Engage in Continuous Monitoring: Regular reviews of compliance processes and audits will help in recognizing areas of improvement.
• Leverage Technology: Utilize software solutions for tracking compliance metrics associated with controlled substances, enhancing accuracy and reducing human error.

Practical Tips for Documentation and Justification

When addressing regulatory compliance in the context of controlled substances, the following practical tips can be useful:

• Justification for Bridging Data: Clearly outline the rationale for using bridging data in submissions if the controlled substance has been approved in other regions. This should also include a scientific justification to support safety and efficacy claims.
• Controlled Substance Registrations: Ensure that any registrations relevant to changing product formulations or indications for controlled substances are maintained and current, considering local requirements.
• Tracking Changes in Regulations: Stay abreast of changes in regulations regarding controlled substances, especially as they may shift between regions or could impact previously approved submissions.
• Request Feedback from Audits: Use feedback obtained from previous audits to adjust practices and documentation processes proactively.

Conclusion

Audit risks and legal exposure management within the pharmaceutical landscape, especially concerning controlled substances, is a multifaceted process that demands attention to detail, compliance with robust regulations, and effective interdepartmental collaboration. By understanding regulatory expectations, enhancing documentation practices, and implementing risk management strategies, organizations can not only reduce the likelihood of non-compliance but also ultimately lessen the associated costs, risks, and rework. In a sector where regulatory scrutiny is paramount, the proactive engagement of Regulatory Affairs ensures a solid foundation for both current and future operations.